HomeCompareVCTTF vs MRK

VCTTF vs MRK: Dividend Comparison 2026

VCTTF yields 1818.18% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VCTTF wins by $4103414683.78M in total portfolio value
10 years
VCTTF
VCTTF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full VCTTF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VCTTF vs MRK

📍 VCTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCTTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCTTF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCTTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCTTF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, VCTTF beats the other by $3,147,377,270,434,617.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCTTF + MRK for your $10,000?

VCTTF: 50%MRK: 50%
100% MRK50/50100% VCTTF
Portfolio after 10yr
$2051707341.95M
Annual income
$1,851,398,394,383,102.50/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VCTTF
No analyst data
Altman Z
1.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCTTF buys
0
MRK buys
0
No recent congressional trades found for VCTTF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCTTFMRK
Forward yield1818.18%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4103414683.84M$56.8K
Annual income after 10y$3,702,796,788,756,407.00$9,798.13
Total dividends collected$4074760433.31M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCTTF vs MRK ($10,000, DRIP)

YearVCTTF PortfolioVCTTF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$192,518$181,818.18$11,206$366.19+$181.3KVCTTF
2$3,477,331$3,271,336.99$12,650$502.35+$3.46MVCTTF
3$58,943,217$55,222,471.89$14,407$694.19+$58.93MVCTTF
4$937,891,469$874,822,227.57$16,585$967.82+$937.87MVCTTF
5$14,012,869,532$13,009,325,660.38$19,342$1,363.89+$14012.85MVCTTF
6$196,647,994,247$181,654,223,846.76$22,913$1,947.19+$196647.97MVCTTF
7$2,592,865,386,485$2,382,452,032,641.56$27,662$2,823.89+$2592865.36MVCTTF
8$32,132,661,421,271$29,358,295,457,731.54$34,159$4,173.35+$32132661.39MVCTTF
9$374,409,247,740,494$340,027,300,019,734.44$43,337$6,308.80+$374409247.70MVCTTF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$56,776$9,798.13+$4103414683.78MVCTTF

VCTTF vs MRK: Complete Analysis 2026

VCTTFStock

Vection Technologies Limited, an enterprise-focused company, that helps businesses in bridging the physical and digital worlds in Australia. The company operates in two segments, IT Development and Outsourced Services. It offers Mindesk, a virtual reality design review and real-time rendering in the unreal engine, for CAD and BIM; EnWorks, a solution to support training, manufacturing, and maintenance processes that enhances the work with augmented reality-powered visual assistance; 3DFrame, a no-code enterprise metaverse app for immersive product presentations; configuration that manages product variations for ecommerce, from web to mobile devices; and XRKiosk, which transforms the in-store customer experience with 3D and augmented reality. It serves automotive, naval, furniture, fashion, and education industries for design review, training, remote presentations, retail 3D experience, and 3D e-commerce applications. The company was formerly known as ServTech Global Holdings Limited and changed its name to Vection Technologies Limited in November 2019. Vection Technologies Limited was incorporated in 2016 and is based in Osborne Park, Australia.

Full VCTTF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VCTTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCTTF vs SCHDVCTTF vs JEPIVCTTF vs OVCTTF vs KOVCTTF vs MAINVCTTF vs JNJVCTTF vs ABBVVCTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.